Michael Cole Engling, PT, DPT, LAT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 268 Nolan Ave., Kaycee, WY 82639 Phone: 307-738-2360 |
News Archive
Connecticut Children's Medical Center and Anthem Blue Cross and Blue Shield announced today that they have reached a multi-year agreement, ending a two-month dispute that led to uncertainty and confusion for many patients and their families. The hospital and the Connecticut Children's Specialty Group had dropped the insurer April 16 after both sides failed to reach an agreement after a year of negotiations. Under the deal, Anthem will immediately resume covering in-network costs.
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the official change of its name to the Cell and Gene Therapy Catapult.
Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).
Smokers who want to quit now have up to nine times greater chance of doing so, thanks to new DNA testing launched today by Oxford University's newest spin-out, G-Nostics.
American International Biotechnology Services (AIBioTech), a division of Bostwick Laboratories, Richmond, VA, today announced that it is one of four contractors awarded a new government contract valued at approximately $21 million. AIBioTech provides integrated research and development sciences and clinical testing services to physicians and life sciences investigators in biotechnology and pharmaceutical companies, academic institutions, and government agencies. The new contract will be funded in phases, with the first AIBioTech phase valued at nearly $3 million. AIBioTech has assembled a consortium of seven leading technology and biotechnology companies who are poised to meet all of the anticipated scientific objectives.
› Verified 8 days ago